In summary, mIDH-selective PET tracers could be relevant for several preclinical and clinical applications, which include non-invasive assessment of the IDH status and tumor delineation in glioma patients, longitudinal studies on mIDH expression in preclinical and clinical settings as well as in vivo target engagement and occupancy studies with mIDH-targeted drugs. This evidence concerns the gene IDH1 and glioma.